Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase(CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

Autor: Steegmann, Juan Luis, Montero, Luis Felipe Casado, Gomez-Casares, Maria Teresa, Rozman, Maria, Echeveste, Maria Asuncion, Garcia-Gutierrez, J. Valentin, Sastre, Jose Luis, Payer, Angel Ramirez, Olavarria, Eduardo, Vall, Ferran, Blanca Xicoy, Giraldo, Pilar, Conde, Eulogio, Vallansot, Rolando Omar, Lopez-Lorenzo, Jose Luis, Palomera, Luis, Ruiz, Soraya, Casas, Laura, Walasek, Claudia, Colomer, Dolors

Publikováno v: ResearcherID

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::862941651973811a615295dda1443357
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000331385009038&KeyUID=WOS:000331385009038

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.

Autor: Schey S; King's College Hospital, London, UK., Montero LFC; Hospital Virgen de la Salud, Toledo, Spain., Stengel-Tosetti C; Dolon Ltd., London, UK., Gibson CJ; Celgene Corporation, Summit, NJ USA., Dhanasiri S; Celgene International, Boudry, Switzerland.

Publikováno v: Oncology and therapy [Oncol Ther] 2017; Vol. 5 (1), pp. 31-40. Date of Electronic Publication: 2017 Jan 03.